SCHEMBL2239617

SCHEMBL2239617

O=C(NCc1ccc(-c2ccccc2)o1)c1ccc2ncccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.51
NAMPT P43490 1/20 0.49
BCAT1 P54687 1/20 0.48
RAB9A P51151 3/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC2 Q92769 1/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
ADRA1D P25100 1/20 0.47
HTR2A P28223 1/20 0.47
ADRA1A P35348 1/20 0.47
HRH1 P35367 1/20 0.47
ADRA1B P35368 1/20 0.47
DRD3 P35462 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12352610 0.85 PLK1 (0.54) PLK1BCAT1RAB9AMAPTALDH1A1
SCHEMBL1680726 0.83 PLK1 (0.54) PLK1BCAT1RAB9AMAPTALDH1A1
SCHEMBL1680911 0.82 PLK1 (0.48) PLK1BCAT1RAB9AMAPTALDH1A1
SCHEMBL12361022 0.81 MMP13 (0.59) PLK1NAMPTBCAT1RAB9AHDAC1
SCHEMBL3213042 0.80 PLK1 (0.62) PLK1NAMPTBCAT1RAB9AMAPT
SCHEMBL1680953 0.79 PLK1 (0.54) PLK1NAMPTBCAT1RAB9AMAPT
SCHEMBL13491462 0.78 HPGD (0.69) PLK1RAB9AMAPTALDH1A1NPC1
SCHEMBL1680949 0.76 EGLN1 (0.54) PLK1RAB9AMAPTALDH1A1HDAC1
SCHEMBL1680963 0.76 HDAC6 (0.58) PLK1NAMPTBCAT1HDAC1HDAC2
SCHEMBL1681082 0.76 PLK1 (0.60) PLK1NAMPTBCAT1MAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 PLK1 928/4885NAMPT 1609/4885BCAT1 1967/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 PLK1 1133/4885NAMPT 1668/4885BCAT1 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.